Simulect

Simulect

basiliximab

Manufacturer:

Novartis

Distributor:

DKSH
Concise Prescribing Info
Contents
Basiliximab
Indications/Uses
Prophylaxis of acute organ rejection in de novo renal transplantation in adult & childn, to be used concomitantly w/ ciclosporin & corticosteroid-based immunosuppression; or in a triple therapy regimen w/ ciclosporin, corticosteroids & either azathioprine or mycophenolate mofetil.
Dosage/Direction for Use
2 doses, the 1st dose w/in 2 hr before transplantation surgery & the 2nd dose 4 days after transplantation. Adult & childn ≥35 kg 20 mg/dose;<35 kg 10 mg/dose.
Contraindications
Special Precautions
Discontinue use if severe hypersensitivity reactions occur. Increased risk of developing lymphoproliferative disorders & opportunistic infections eg, cytomegalovirus. Not recommended w/ live vaccines for immunosuppressed patients. Women of childbearing potential should use effective contraception for 4 mth after last dose. Pregnancy & lactation (4 mth after last dose).
Adverse Reactions
Constipation, UTI, HTN, URTI. Adult: Pain, nausea, peripheral edema, anaemia, headache, hyperkalaemia, hypercholesterolaemia, post-op wound complication, wt gain, increased blood creatinine, hypophosphataemia, diarrhea. Childn: Hypertrichosis, rhinitis, pyrexia & viral infection, sepsis.
MIMS Class
Immunosuppressants
ATC Classification
L04AC02 - basiliximab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Simulect powd for inj/infusion (vial) 20 mg
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in